Margaret R. Walker

Margaret R. Walker

Auto-generated profile, based on publicly available information

Margaret R. Walker

Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2025 in Journal of the American College of Radiology
Verified
Journal Article
Closed access
MWMargaret R. Walker
Margaret R. Walker
KBKyle A. Burton
Kyle A. Burton
DCDiego E. Collazo-Irizarry
Diego E. Collazo-Irizarry
WSWade Swenson
Wade Swenson
JPJoshua C. Pritchett
Joshua C. Pritchett
ANAnand K. Narayan
Anand K. Narayan

19 April 2025 in Cancer Medicine
Verified
Journal Article
Open access
BKBroc S. Kelley
Broc S. Kelley
CCCibele B. Carroll
Cibele B. Carroll
JHJohn M. Hampton
John M. Hampton
MWMargaret R. Walker
Margaret R. Walker
SZSyed Nabeel Zafar
Syed Nabeel Zafar
NLNoelle K. LoConte
Noelle K. LoConte
Purpose: Recent work noted lower overall survival (OS) in American Indian/Alaskan Native (AI/AN) individuals diagnosed with colon cancer compared with non‐Hispanic White (NHW) individuals. Rectal cancer demographic profiles at diagnosis and survival outcomes have not been reported. We sought to identify differences in rectal cancer diagnosis and outcomes between AI/AN and White populations.Methods: White and AI/AN patients aged 18 or older, diagnosed between 2004 and 2020 with rectal adenocarcinoma were identified within the National Cancer Database (NCDB). Unadjusted and adjusted analyses were used to evaluate demographic and clinical standardized differences (stddiff) between AI/AN and White patients. Survival analyses of those diagnosed with locally advanced rectal cancer (Stage II/III) were performed using the Kaplan–Meier methods and multivariate Cox‐proportional hazards modeling.Results: 176,341 eligible cases were identified: 0.6% were AI/AN (N = 992) and 99.4% White (N = 175,349). Compared to the White population, AI/AN patients were younger at diagnosis (mean age 59.9 vs. 64.5 years; stddiff = 0.36) and had more advanced stage disease (44.8% vs. 43.7%; stddiff = 0.15). A higher percentage of AI/AN resided in the areas of the lowest median income (35.5% vs. 15.1%; stddiff = 0.62) per zip code, rural (9.9% vs. 2.2%; stddiff = 0.65), and used Medicaid as their primary payor (14.3% vs. 6.2%; stddiff = 0.63). Adjusted analyses suggest the AI/AN group has an increased hazard of death compared with the White population (HR, 1.14; 95% CI, 1.05–1.25; p = 0.003).Conclusions: AI/AN patients with rectal cancer have a younger age and a more advanced stage at diagnosis. AI/AN race is associated with lower OS compared to White patients in multivariable analyses. Future efforts should focus on increasing colorectal cancer screening and access to treatment for AI/AN populations in an attempt to improve survival outcomes.

11 March 2024 in Cancer Medicine
Verified
Journal Article
Open access
MWMargaret R. Walker
Margaret R. Walker
KLKha Lor
Kha Lor
KLKajua B. Lor
Kajua B. Lor
RVRoberto J. Vidri
Roberto J. Vidri
JHJohn M. Hampton
John M. Hampton
NLNoelle K. LoConte
Noelle K. LoConte
Background: The Hmong population constitutes an independent ethnic group historically dispersed throughout Southeast Asia; fallout from the Vietnam War led to their forced migration to the United States as refugees. This study seeks to investigate characteristics of the Hmong population diagnosed with in colorectal cancer (CRC) as well as survival within this population.Methods: Cases of colon and rectal adenocarcinoma diagnosed between 2004 and 2017 were identified from the National Cancer Database (NCDB). Summary statistics of demographic, clinical, socioeconomic, and treatment variables were generated with emphasis on age and stage at the time of diagnosis. Cox‐proportional hazard models were constructed for survival analysis.Results: Of 881,243 total CRC cases within the NCDB, 120 were classified as Hmong. The average age of Hmong individuals at diagnosis was 58.9 years compared 68.7 years for Non‐Hispanic White (NHW) individuals (p < 0.01). The distribution of analytic stage differed between the Hmong population and the reference NHW population, with 61.8% of Hmong individuals compared to 45.8% of NHW individuals with known stage being diagnosed at stage III or IV CRC compared to 0, I, or II (p = 0.001). However, there was no difference in OS when adjusting for potential confounders (HR 1.00 [0.77–1.33]; p = 0.998).Conclusions: Hmong individuals are nearly a decade younger at the time of diagnosis of CRC compared to the NHW individuals. However, these data do not suggest an association between Hmong ethnicity and overall survival, when compared to the NHW population.

1 April 2022 in Journal of Hematology
Verified
Journal Article
Open access
MWMargaret Walker
Margaret Walker
MFMatthew Folstad
Matthew Folstad
KSKelcy Smith-Simmer
Kelcy Smith-Simmer
ERErica Reinig
Erica Reinig
KNKalyan Nadiminti
Kalyan Nadiminti
LBLauren G. Banaszak
Lauren G. Banaszak
Isolated myeloid sarcoma is an uncommon subtype of acute myeloid leukemia associated with variable prognosis. We present the case of a previously healthy 30-year-old man presenting with chest pain and weight loss who was found to have a large mediastinal mass. Biopsy of the mass was consistent with isolated myeloid sarcoma. A somatic tumor sequencing panel revealed au EGFR T790M variant, which was later confirmed to be of germline origin. Germline EGFR T790M variants are associated with a hereditary predisposition to lung cancer, though myeloid malignancies have not yet been described. To our knowledge, this is the first reported case of myeloid sarcoma in a patient with an underlying germline EGFR T790M mutation. As somatic tumor sequencing panels become more commonplace, it is important to recognize potential germline variants in order to facilitate appropriate refenal for genetic counseling, perform confamatory genetic testing, and to develop a personalized treatment and surveillance plan for patients and their families.